IGM Biosciences Inc. (IGMS)
1.22
0.03 (2.52%)
At close: Apr 17, 2025, 3:59 PM
1.21
-0.44%
After-hours: Apr 17, 2025, 07:56 PM EDT
2.52% (1D)
| Bid | 1.14 |
| Market Cap | 72.93M |
| Revenue (ttm) | 2.68M |
| Net Income (ttm) | -195.79M |
| EPS (ttm) | -3.24 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | -2.09 |
| Analyst | Hold |
| Ask | 1.35 |
| Volume | 76,415 |
| Avg. Volume (20D) | 263,277 |
| Open | 1.18 |
| Previous Close | 1.19 |
| Day's Range | 1.18 - 1.25 |
| 52-Week Range | 0.92 - 22.50 |
| Beta | 0.57 |
About IGMS
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinica...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2019
Employees 149
Stock Exchange NASDAQ
Ticker Symbol IGMS
Website https://igmbio.com
Analyst Forecast
According to 8 analyst ratings, the average rating for IGMS stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 63.93% from the latest price.
Stock ForecastsNext Earnings Release
IGM Biosciences Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-66.29%
IGM Biosciences shares are trading lower after the...
Unlock content with
Pro Subscription
4 months ago
+8.99%
IGM Biosciences shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating on the stock and announced a price target of $21.
